首页> 外文期刊>Human gene therapy. Clinical development >Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II
【24h】

Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II

机译:造血干细胞基因治疗纠正II型粘多糖贮积症小鼠模型中的神经病性表型。

获取原文
获取原文并翻译 | 示例
           

摘要

Mucopolysaccharidosis type II (MPS II) is a neuropathic lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS), which leads to the accumulation of glycosaminoglycans (GAGs). We demonstrated that biochemical alterations in the brains of MPS II mice are not corrected by bone marrow transplantation (BMT) or enzyme replacement therapy, although BMT has been shown to be effective for other neurodegenerative MPSs, such as Hurler syndrome. In this study, we demonstrated that lentiviral isogeneic hematopoietic stem cell (HSC) gene therapy corrected neuronal manifestations by ameliorating lysosomal storage and autophagic dysfunction in the brains of MPS II mice. IDS-transduced HSCs increased enzyme activity both in various visceral organs and the CNS. Decreased levels of GAGs were observed in many organs, including cerebra, after transplantation of IDS-transduced HSCs. In addition, lentiviral HSC gene therapy normalized the secondary accumulation of autophagic substrates, such as p62 and ubiquitin-protein conjugates, in cerebra. Furthermore, in contrast to naive MPS II mice, there was no deterioration of neuronal function observed in transplant recipients. These results indicated that lentiviral HSC gene therapy is a promising approach for the treatment of CNS lesions in MPS II.
机译:II型粘多糖贮积病(MPS II)是一种神经病性溶酶体贮积病,由缺乏的氨基二糖基-2-硫酸酯酶(IDS)引起,导致糖胺聚糖(GAGs)的积累。我们证明了MPS II小鼠大脑中的生化改变没有通过骨髓移植(BMT)或酶替代疗法得到纠正,尽管BMT已被证明对其他神经退行性MPS有效,例如Hurler综合征。在这项研究中,我们证明了慢病毒同基因造血干细胞(HSC)基因疗法可通过改善MPS II小鼠大脑中的溶酶体贮藏和自噬功能障碍来纠正神经元表现。 IDS转导的HSC在各种内脏器官和CNS中均增加了酶活性。移植IDS的HSC后,在包括大脑在内的许多器官中均观察到GAG的水平降低。此外,慢病毒HSC基因疗法可正常化自噬底物(例如p62和泛素-蛋白质结合物)在大脑中的二次蓄积。此外,与幼稚的MPS II小鼠相比,在移植受体中未观察到神经元功能的恶化。这些结果表明,慢病毒HSC基因疗法是治疗MPS II中CNS病变的一种有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号